Rophelbio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Out of Business

Rophelbio General Information

Description

Developer of anticancer drugs designed to treat cancer. The company is engaged in developing a new biomarker that can diagnose cancer and an anticancer drug that can treat triple-negative breast and colorectal cancer, enabling patients to treat cancer and stay healthy.

Contact Information

Website
rophelbio.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 1208 / B102, 31, Ttukseom-ro 1-gil
  • Seongdong
  • Seoul
  • South Korea
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1208 / B102, 31, Ttukseom-ro 1-gil
  • Seongdong
  • Seoul
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rophelbio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Jan-2023 Completed Out of Business
3. Early Stage VC 22-Dec-2021 Completed Startup
2. Seed Round 16-Sep-2020 Completed Startup
1. Accelerator/Incubator 31-May-2020 Completed Startup
To view Rophelbio’s complete valuation and funding history, request access »

Rophelbio Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • Pending

  • Expiring in next 12 mo

Rophelbio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023195783-A1 Use of drg2 as biomarker for predicting ovarian metastasis of cancer Inactive 06-Apr-2022
WO-2023038375-A1 Use of drg2 as biomarker Inactive 07-Sep-2021
WO-2023277481-A1 Composition comprising drg2 inducer for preventing or treating sepsis Inactive 01-Jul-2021
WO-2022119349-A1 Composition for suppressing resistance to kras inhibitor Inactive 04-Dec-2020
US-20230287505-A1 Biomarker for cancer immunotherapy and use thereof Inactive 30-Mar-2020 C12Q1/6886
To view Rophelbio’s complete patent history, request access »

Rophelbio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Rophelbio FAQs

  • When was Rophelbio founded?

    Rophelbio was founded in 2019.

  • Where is Rophelbio headquartered?

    Rophelbio is headquartered in Seoul, South Korea.

  • What is the size of Rophelbio?

    Rophelbio has 6 total employees.

  • What industry is Rophelbio in?

    Rophelbio’s primary industry is Biotechnology.

  • Is Rophelbio a private or public company?

    Rophelbio is a Private company.

  • What is Rophelbio’s current revenue?

    The current revenue for Rophelbio is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process